BUFFALO, NY--(Marketwire - October 15, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on October 14, the first healthy volunteer was dosed in the initial human safety study for Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS).